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Background: Breastfeeding is considered as gold standard for infant nutrition and should be 
interrupted only when a compelling indication exists. Certain medical conditions such as abortion, 
stillbirth, HIV infection, or infant galactosemia and certain medications such as chemotherapy 
necessitate lactation inhibition to protect the health of mother and infant. Drug use evaluation 
(DUE) studies are done to explore the current practice in a setting and help to identify areas in 
which further information and education may be needed by clinicians.
Objective: The aim of this study was to conduct a DUE of cabergoline to assess indications 
for lactation inhibition, dosage regimen, and its safety.
Method: A retrospective cross-sectional DUE study was conducted over a period of 4 months 
from September 1, 2013, till December 31, 2013, at the Women’s Hospital, Qatar. All caber-
goline prescriptions written for lactation inhibition within 10 days of delivery or abortion were 
included in the study. A descriptive data analysis was undertaken.
Results: Of the 85 patients included, stillbirth (50.6%) was considered as the main reason for 
lactation inhibition, followed by abortion (27.1%) and neonatal death (12.9%). The remaining 
9.4% of the patients had live baby, and the majority of them were prescribed cabergoline for 
lactation inhibition because their maternal medical conditions required the use of drugs with 
insufficient safety data (n=6). Seventy-four percent of patients received cabergoline at accurate 
time and dose. However, 14% of the patients had preexisting hypertensive disorder and 58.3% 
of them were diagnosed as uncontrolled hypertension.
Conclusion: The current DUE study found that cabergoline was mainly used to inhibit lacta-
tion for patients with stillbirth, abortion, and neonatal death. In mothers who use medications 
for other medical conditions, benefits and risks of breastfeeding should be carefully balanced 
before prescribing cabergoline. Current prescribing pattern can be further enhanced through 
informing health care providers regarding appropriate cabergoline dosage regimen and its safety 
in patients with uncontrolled hypertension.
Keywords: lactation inhibition, cabergoline, drug use evaluation, breastfeeding inhibition
Introduction
Human milk is the normative standard for infant feeding and nutrition. It provides 
short- and long-term nutritional, cognitive, emotional, and immunologic advantages. 
Medical contraindications to breastfeeding are few. These include infant galactosemia 
or mother’s HIV infection, untreated and active tuberculosis, or use of some che-
motherapy agents. Furthermore, some mothers avoid breastfeeding on personal or 
social grounds. Regardless of the reason for not breastfeeding, this decision can be 
associated with complications including milk secretion, breast pain, engorgement, or 
mastitis.1–7
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Various approaches are used to suppress lactation in 
women. Severe breast pain can be encountered in women who 
do not breastfeed and use analgesics or use nonpharmacologi-
cal approaches to suppress lactation such as breast binder or ice 
packs.8 Furthermore, the use of pharmacological interventions 
such as estrogens alone, estrogen–androgen combination, pyri-
doxine, and dopamine agonists have been evaluated for efficacy 
in milk suppression and have shown variable results.5
Cabergoline is a dopamine agonist used to suppress 
lactation despite the lack of approval from the United States 
Food and Drug Administration for this indication. It exerts 
its effect through the inhibition of prolactin release from the 
anterior pituitary gland. Compared to bromocriptine, the 
older dopamine agonist, cabergoline is better tolerated with 
significantly less rebound breast activity and adverse effects 
and with more simple administration schedule.9,10
A number of studies have been conducted to examine 
the dose-dependent effect of cabergoline.11–14 A range of 
oral doses between 0.4 mg and 1 mg was used, and the most 
effective dose for long-term suppression of lactation was 
found to be 1 mg.15 Accordingly, a single dose of 1 mg during 
the first 24–27 hours postpartum is recommended for lactation 
inhibition,10,16 while a dose of 0.25 mg every 12 hours for four 
doses is used for suppression of established lactation.16
Drug use evaluation (DUE) is a process of ongoing, system-
atic, criteria-based evaluation of drug use with the aim of ensur-
ing that medications are used appropriately at the individual 
patient level.17 DUE studies are a powerful tool to explore the 
pattern of prescribing medications, promote optimal medication 
therapy, and prevent medication-related problems. In addition, 
DUE studies help to identify areas in which further education 
or information may be needed by health care providers.17
A valid indication is necessary for the use of cabergoline 
to inhibit lactation in nursing mothers. Physicians must be 
aware of the dose, indication, and frequency to prescribe cab-
ergoline in nursing mothers. They also should review mater-
nal medical conditions to ensure its safety. Therefore, we 
aimed to conduct a DUE of cabergoline to assess indications 
for lactation inhibition, dosage regimen, and its safety.
Method
study setting and period
This DUE study was conducted at the Women’s Hospital, 
Qatar. This tertiary care facility has 234 beds including antena-
tal, postnatal, and high dependency units, an outpatient depart-
ment followed by an emergency room, 16 labor rooms, and 
three operating theaters, as well as a level-3 neonatal intensive 
care unit. All cabergoline prescriptions for lactation inhibition 
written over a 4-month period between September 1, 2013, 
and December 31, 2013, were used in the study.
study design
This retrospective cross-sectional study was conducted to 
evaluate the use of cabergoline in lactation inhibition. A 
literature review along with World Health Organization 
guidelines on conducting DUE studies was utilized for the 
DUE criteria selection.17 The primary outcomes for the 
study were
1. Identify and assess indications for lactation inhibition.
2. Evaluate the appropriateness of cabergoline dosage 
regimen.
3. Evaluate the safe use of cabergoline in patients with 
existing medical comorbidities.
eligibility criteria
Women who received a cabergoline prescription for lacta-
tion inhibition within 10 days of delivery or abortion were 
included in the study.
Data collection
A standardized data collection tool was developed utilizing 
the selected DUE criteria. Variables were designated to 
measure the prespecified outcomes. The tool was validated 
through piloting it on ten randomly selected files.
Outcome measures
The Centers of Disease Control and Prevention and American 
Academy of Pediatrics resources were utilized to identify the 
medical conditions that necessitate lactation inhibition.18,19 
Drugs in Pregnancy and Lactation book and Drugs and 
Lactation Database (LactMed) by the US National Library 
of Medicine were used to identify the safety of medications 
with breastfeeding.15,20 A single dose of 1 mg of cabergoline 
within the first 24–27 hours of delivery/abortion is the recom-
mended regimen for lactation inhibition.10,16 The main safety 
concerns for the use of cabergoline that were evaluated in 
this study were preexisting uncontrolled hypertension at the 
time of cabergoline administration and allergy with ergot 
alkaloid since the use of cabergoline in these populations 
could cause significant risk to patients.
Definitions
In this study, lactation inhibition refers to the prevention of 
milk formation within the first 27 hours postpartum before 
the mother starts breastfeeding, whereas lactation suppres-
sion pertains to suppression of established lactation. There is 
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no clear definition and duration for controlled hypertension 
before cabergoline administration. So we defined controlled 
hypertension as having systolic blood pressure ,150 mmHg 
and diastolic blood pressure ,100 mmHg21 within the 
previous 24 hours before prescribing cabergoline without 
intravenous antihypertensive medications to control the 
blood pressure.
Data processing and analysis
Data collection was done using patients’ medical records, 
and the collected data were manually sorted and categorized. 
A descriptive data analysis was carried out and evaluated 
against the preset criteria.
ethical consideration
Waiver of informed consent and ethical approval were 
obtained from the Medical Research Center, Hamad Medical 
Corporation (approval number 13393/13).
Results
A total of 232 patients were prescribed cabergoline, of which 
85 patients were included in this study (Figure 1). Demo-
graphic characteristics of patients are shown in Table 1. 
Thirty-one percent of the patients were Qataris, and the major-
ity of the patients had a singleton pregnancy (90.6%).
indications for lactation inhibition
Stillbirth was found to be the main reason to inhibit lactation 
(50.6%), followed by abortion (27.1%) and neonatal death 
(12.9%). Only 9.4% of the patients who received cabergoline 
for lactation inhibition had live baby (Table 2).
appropriateness of indications for 
lactation inhibition
Following abortion, only one patient received cabergoline 
at gestational age ,16 weeks as patient requested, whereas 
all the other patients received cabergoline at a higher ges-
tational age.
In patients with live baby, no infant or maternal medical 
conditions that required lactation inhibition were encoun-
tered. One of the patients with severely inverted nipples 
requested cabergoline to suppress her lactation. Six patients 
who used medications for postkidney transplant, depression, 
epilepsy, and cardiomyopathy did not breastfeed their babies. 
All these patients were using combinations of medications 
(Table 2). Only one patient requested lactation inhibition 
with no clear reason.
Cabergoline dosage
The majority of the patients were prescribed cabergoline dur-
ing hospital admission (83.5%), while the rest were prescribed 
cabergoline at discharge as home medication. Cabergoline 
was prescribed within the first 27 hours of delivery or abortion 
in .80% of the patients and was prescribed as a single dose 
of 1 mg in 71.8% of the patients. Appropriate prescribing 
pattern of both timing and dose was found in 74.1% of the 
patients (Table 3). It was noted that 50% of the patients with 
live baby received cabergoline after 27 hours of delivery.
Figure 1 Patients selection for inclusion.
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safety of administration
Fourteen percent of the patients had hypertensive dis-
orders during current pregnancy. Fifty-eight percent of 
these patients had uncontrolled blood pressure 24 hours 
prior to prescribing cabergoline (Figure 2). None of the 
patients who received cabergoline were allergic to ergot 
alkaloids (Table 1).
Discussion
This DUE study explores the current clinical practice and 
provides an evidence for the use of cabergoline in lactation 
inhibition with an emphasis on the indications and safety. To 
the best of our knowledge, no DUE studies on cabergoline 
use for lactation inhibition were published elsewhere.
Lactogenesis starts at ~16 weeks of gestation.22,23 Most 
of the patients received cabergoline at late gestational ages. 
Only 9.4% of the patients who received cabergoline had 
live baby. The main reason for that was the use of other 
medications by the mothers for their existing maternal 
comorbidities. Not all the received medications contraindi-
cate breastfeeding,15,20 but may be the use of combinations of 
these medications led to the decision of lactation inhibition. 
Table 2 indication for lactation inhibition
Indication n (%) Comments
abortion 23 (27.1)
,16 weeks 1 at 7 weeks, patient 
request
16–20 weeks 6
21–23 weeks 16
stillbirth 43 (50.6)
neonatal death 11 (12.9)
live infant 8 (9.4)
infant medical condition 0
Maternal structural problems 1 severely inverted 
nipples
Maternal infection/medical condition 0
Medication/chemicals usea 6
Others 1 Unclear reason, 
patient request
Notes: aMedications used by each patient: Patient 1: prednisolone 5 mg daily, 
rosuvastatin 10 mg daily, tacrolimus 4 mg am and 3 mg pm, mycophenolate 1 g BiD, 
kidney transplant. Patient 2: azathioprine 75 mg daily, tacrolimus 3 mg BiD, prednisolone 
5 mg daily, kidney transplant. Patient 3: amitriptyline 75 mg daily, fluphenazine 0.5 mg 
daily, nortriptyline 10 mg daily, depression. Patient 4: amitriptyline 25 mg daily, fluoxetine 
20 daily, depression. Patient 5: oxcarbazepine 300 mg BiD, levetiracetam 500 mg TiD, 
epilepsy. Patient 6: carvedilol 12.5 mg BiD, furosemide 40 daily, cardiomyopathy.
Abbreviations: BiD, twice daily; TiD, three times daily.
Table 3 Dosage regimen of cabergoline
Cabergoline prescription n (%)
Cabergoline prescription written for
in-patient administration 71 (83.5)
home administration 14 (16.5)
Timing between abortion/delivery and writing prescription
#27 hours 71 (83.5)
.27 hours 14 (16.5)
abortion 4
stillbirth 3
neonatal death 3
live baby 4
Dosing
1 mg single dose 61 (71.8)
0.25 mg twice daily for four doses 21 (24.7)
Othersa 3 (3.5)
Proper timing and dosing of cabergoline 63 (74.1)
Note: aOthers (n): 1 mg for two doses 1 week apart (1), 0.5 mg single dose (2).
Table 1 Demographic characteristics
Variables n (%)
age (years)
,20 1 (1.2)
20–29 35 (41.2)
30–39 38 (44.7)
.40 11 (12.9)
nationality
Qatari 27 (31.8)
gulf Cooperation Council countries 7 (8.2)
egyptian 7 (8.2)
indian 6 (7.1)
Filipino 6 (7.1)
Othersa 32 (37.6)
gravidityb
1 24 (28.2)
$2 59 (69.4)
Parityb
0 27 (31.8)
1 24 (28.2)
$2 32 (37.6)
number of pregnancies
singleton 77 (90.6)
Twins 7 (8.2)
Triplets 1 (1.2)
allergy
ergot alkaloid 0
Notes: aOthers (n): Yemeni (5), Pakistani (5), sudanese (4), Jordanian (4), iranian (2), 
Palestinian (2), lebanese (2), Bangladeshi (2), indonesian (1), Moroccan (1), nepalese 
(1), Mauritian (1), syrian (1), and senegalese (1). bData are missed for two patients.
Figure 2 Cabergoline safety.
Note: Total patients n=85, patients with blood pressure disorder n=12.
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Generally, for many of the medications that possess a low 
risk to the nursing baby, breastfeeding can be continued with 
close monitoring of the baby and with proper timing between 
medication administration and breastfeeding if applicable or 
a safer alternative can be used when appropriate.
Many studies assessed the prolactin inhibitory effect of 
different cabergoline doses, and the 1 mg single dose was 
shown to be the most effective dose.13,14 In our study, the 
1 mg single dose was prescribed in 71.8% of the patients. 
Cabergoline administration should take place within the first 
24–27 hours of delivery.10,16 Delay beyond this time period 
was noted in 50% of the patients with live baby, which might 
reflect delay in making the decision of stopping breastfeeding 
until weighing benefits and risks.
Cabergoline should not be used in women with 
pregnancy-induced hypertension, for example, preeclampsia 
or postpartum hypertension, unless the potential benefit is 
judged to outweigh the possible risk.16 Hypertensive disorders 
were encountered in 12 patients, with 58.3% of them having 
uncontrolled blood pressure for the 24 hours prior to receiv-
ing cabergoline. Close monitoring of these patients would 
be required, especially for blood pressure.
One of the limitations of the study was its retrospec-
tive nature that does not provide information about all 
perspectives of the physicians and patients at the time of 
prescribing cabergoline. Moreover, unclear and incomplete 
documentation might reduce the amount of information 
that could be retrieved. Another limitation is that this DUE 
assesses the timing of writing the prescription, which might 
not reflect the exact time of administration, especially with 
patients who were planned to receive it at discharge as home 
medication.
Our study described different aspects of clinical practice 
regarding cabergoline use in lactation inhibition. Future work 
can be expanded to the evaluation of cabergoline in lactation 
suppression within the first 2–6 months postpartum, with a 
focus on patients with live nursing babies.
Conclusion
This DUE study found that cabergoline use in lactation 
inhibition was mainly for patients with stillbirth, abortion, 
and neonatal death. Maternal use of medications for other 
medical comorbidities requires careful evaluation of breast-
feeding benefits and risks before prescribing cabergoline. To 
further enhance the current prescribing pattern, health care 
providers need to be informed regarding the appropriate dose, 
frequency, and safety concerns in patients with uncontrolled 
hypertension.
Funding
This work received a grant from the Medical Research 
Center, Hamad Medical Corporation, Qatar.
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